Sean Ainsworth, Chairman and CEO

Oct. 13 | 3:15pm | BlueRock Therapeutics Ballroom

Seattle, WA


In-person Presentation

Immusoft is developing a cutting-edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP). ISP entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.

By using this website you agree to accept our Privacy Policy and Terms & Conditions